Consolidated Portfolio Review Corp Bristol Myers Squibb CO Transaction History
Consolidated Portfolio Review Corp
- $723 Billion
- Q2 2025
A detailed history of Consolidated Portfolio Review Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 45,679 shares of BMY stock, worth $2.1 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
45,679
Previous 45,515
0.36%
Holding current value
$2.1 Million
Previous $2.78 Billion
23.83%
% of portfolio
0.29%
Previous 0.44%
Shares
4 transactions
Others Institutions Holding BMY
# of Institutions
2,668Shares Held
1.64BCall Options Held
22.5MPut Options Held
25.3M-
Vanguard Group Inc Valley Forge, PA195MShares$8.98 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.31 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY108MShares$4.98 Billion0.52% of portfolio
-
State Street Corp Boston, MA94.7MShares$4.36 Billion0.17% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA70.8MShares$3.26 Billion0.59% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $98B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...